Wegovy supply price cut by 40%... to counter Mounjaro

Refund measures for pharmacies are also in place

Except for 2.4 mg, four dosage forms (0.25, 0.5, 1.0, 1.7 mg) will be subject to tiered pricing

노보노디스크 "단일가격→용량별 차등 정책 적용 전격 결정Novo Nordisk “We decided to switch from single-price to tiered pricing policy based on dosage”

The supply price for Wegovy will be reduced by approximately 40% starting on the 14th.

 

Refund measures are also expected to be implemented for pharmacies with inventory.

 

Novo Nordisk notified pharmacies and other relevant parties of the changes through Julic and other channels.

 

According to Dailypharm's coverage, the prices for four dosage forms—0.25mg, 0.5mg, 1.0mg, and 1.7mg—will be reduced, excluding the highest dosage of 2.4mg.

 

The previous single price system will be replaced with a tiered pricing system based on dosage, with the 0.25mg starting dosage set to receive a price cut of around 40%.

 

Once the price reductions are implemented, the purchase prices for pharmacies and clinics will be around KRW 220,000.

 

However, to prevent confusion in medical and pharmacy settings, the specific price reduction rates will not be disclosed.

 

Refunds for existing inventory held by pharmacies will also be processed according to established procedures.

 

Details regarding refund procedures and amounts per pharmacy will be communicated sequentially through Zuellig Pharma sales representatives and the suppliers.

 

Some have speculated that the price reduction policy for Wegovy may be in response to the upcoming launch of Mounjaro this month.

 

Mounjaro, which is expected to be launched around mid-month, will apply tiered pricing across six dosage forms, with the starting dosage being approximately KRW 100,000 cheaper than Wegovy.

 

However, Novo Nordisk stated that it had been reviewing a tiered pricing policy by dosage for a long time after the launch and had decided to switch from a uniform single price system to a tiered pricing system by dosage.

 

A Novo Nordisk representative said, “We decided to lower the shipping price and notify customers to minimize confusion among distributors, pharmacies, and patients who have been prescribed the drug.” They added, “In supplying innovative treatments like Wegovy, we prioritize treatment continuity and accessibility for Korean obesity patients as our top principle, and this principle also applies when determining the shipping price of the treatment.

 

We will continue to strive to improve the obesity treatment environment in Korea through a patient-focused approach.”